» Articles » PMID: 34440687

Familiarity Breeds Strategy: In Silico Untangling of the Molecular Complexity on Course of Autoimmune Liver Disease-to-Hepatocellular Carcinoma Transition Predicts Novel Transcriptional Signatures

Overview
Journal Cells
Publisher MDPI
Date 2021 Aug 27
PMID 34440687
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Autoimmune liver diseases (AILD) often lead to transformation of the liver tissues into hepatocellular carcinoma (HCC). Considering the drawbacks of surgical procedures in such cases, need of successful non-invasive therapeutic strategies and treatment modalities for AILD-associated-HCC still exists. Due to the lack of clear, sufficient knowledge about factors mediating AILD-to-HCC transition, an in silico approach was adopted to delineate the underlying molecular deterministic factors. Parallel enrichment analyses on two different public microarray datasets (GSE159676 and GSE62232) pinpointed the core transcriptional regulators as key players. Correlation between the expression kinetics of these transcriptional modules in AILD and HCC was found to be positive primarily with the advancement of hepatic fibrosis. Most of the regulatory interactions were operative during early (F0-F1) and intermediate fibrotic stages (F2-F3), while the extent of activity in the regulatory network considerably diminished at late stage of fibrosis/cirrhosis (F4). Additionally, most of the transcriptional targets with higher degrees of connectivity in the regulatory network (namely DCAF11, PKM2, DGAT2 and BCAT1) may be considered as potential candidates for biomarkers or clinical targets compared to their low-connectivity counterparts. In summary, this study uncovers new possibilities in the designing of novel prognostic and therapeutic regimen for autoimmunity-associated malignancy of liver in a disease progression-dependent fashion.

Citing Articles

Construction of a Wilms tumor risk model based on machine learning and identification of cuproptosis-related clusters.

Huang J, Li Y, Pan X, Wei J, Xu Q, Zheng Y BMC Med Inform Decis Mak. 2024; 24(1):325.

PMID: 39497055 PMC: 11536559. DOI: 10.1186/s12911-024-02716-8.


The Toll-like receptor 4 antagonist TAK-242 in combination with sodium hyaluronate alleviates postoperative abdominal adhesion in a mouse model.

Liu D, Tong H, Guo Y, Liu B, Ye C, Yang N BMC Med Genomics. 2024; 17(1):257.

PMID: 39456047 PMC: 11520138. DOI: 10.1186/s12920-024-02031-1.


Progression from Non-alcoholic Steatohepatitis to Advanced Liver Diseases and Mortality Among Medicare Patients.

Kim Y, Medicis J, Davis M, Nunag D, Gish R Adv Ther. 2024; 41(11):4335-4355.

PMID: 39316292 PMC: 11480150. DOI: 10.1007/s12325-024-02979-7.


Platelet transfusion enhances pro-aggregatory status shortly after coronary artery bypass grafting (CABG while modulating platelet pro-inflammatory state 1-week post-surgery.

Ahmadi J, Hosseini E, Kargar F, Maghsudlu M, Ghasemzadeh M J Cell Mol Med. 2024; 28(15):e18573.

PMID: 39121235 PMC: 11315096. DOI: 10.1111/jcmm.18573.


lncRNA signature mediates mitochondrial permeability transition-driven necrosis in regulating the tumor immune microenvironment of cervical cancer.

Yi C, Yang J, Zhang T, Xie Z, Xiong Q, Chen D Sci Rep. 2024; 14(1):17406.

PMID: 39075098 PMC: 11286791. DOI: 10.1038/s41598-024-65990-6.


References
1.
Fu Y, Liu S, Zeng S, Shen H . From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019; 38(1):396. PMC: 6734524. DOI: 10.1186/s13046-019-1396-4. View

2.
Bisteau X, Caldez M, Kaldis P . The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations. Cancers (Basel). 2014; 6(1):79-111. PMC: 3980619. DOI: 10.3390/cancers6010079. View

3.
Sucher E, Sucher R, Gradistanac T, Brandacher G, Schneeberger S, Berg T . Autoimmune Hepatitis-Immunologically Triggered Liver Pathogenesis-Diagnostic and Therapeutic Strategies. J Immunol Res. 2019; 2019:9437043. PMC: 6899271. DOI: 10.1155/2019/9437043. View

4.
Menyhart O, Nagy A, Gyorffy B . Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. R Soc Open Sci. 2019; 5(12):181006. PMC: 6304123. DOI: 10.1098/rsos.181006. View

5.
Watanabe T, Soga K, Hirono H, Hasegawa K, Shibasaki K, Kawai H . Features of hepatocellular carcinoma in cases with autoimmune hepatitis and primary biliary cirrhosis. World J Gastroenterol. 2009; 15(2):231-9. PMC: 2653317. DOI: 10.3748/wjg.15.231. View